Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: J Immunol. 2017 May 31;199(1):323–335. doi: 10.4049/jimmunol.1700172

Table I.

Subject characteristics.

Subject Visit Gender Age (years) Disease duration (months) HLA class II1 C-peptide (ng/ml)2 Auto-Abs3
T1D2 1 F 38 28 DRB1*0401/unknown
DQB1*0302/unknown (DQ8)		 1.29 GAD, IA2, Ins
T1D2 2 F 38 31 DRB1*0401/unknown
DQB1*0302/unknown (DQ8)		 0.95 NT4
T1D2 3 F 39 43 DRB1*0401/unknown
DQB1*0302/unknown (DQ8)		 0.41 NT
T1D4 1 M 32 18 DRB1*0401/unknown
DQB1*0302/unknown (DQ8)		 0.27 GAD, IA2, Ins, ZNT8
T1D5 1 M 27 23 DRB1*0401/*13
DQB1*06/unknown		 0.37 GAD, IA2, Ins, ZNT8
HC2 1 F 38 NA5 DRB1*0401/*03
DQB1*02/unknown		 NA NT
HC3 1 F 30 NA DRB1*0401/*03
DQB1*02/unknown		 NA NT
HC5 1 M 30 NA DRB1*0401/1502
DQB1 unknown		 NA NT
1

DRB1 unknown, not DRB1*01, *04, *03, *13, *1501, *1502; DQB1 unknown, not DQB1*02, *0302, *0303; DQB1*06, not *0602 or *0603

2

C-peptide limit of detection, 0.05 ng/ml; subjects were not all fasting at C-peptide determination

3

Auto-Abs, autoantibodies;. Ins autoantibodies may be due to insulin therapy.

4

NT, not tested

5

NA, not applicable